MX2010003881A - El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano. - Google Patents

El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.

Info

Publication number
MX2010003881A
MX2010003881A MX2010003881A MX2010003881A MX2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A MX 2010003881 A MX2010003881 A MX 2010003881A
Authority
MX
Mexico
Prior art keywords
tpora
receptor agonist
myeloid leukemia
human myeloid
thrombopoietin receptor
Prior art date
Application number
MX2010003881A
Other languages
English (en)
Inventor
Connie L Erickson-Miller
Alan M Gewirtz
Anna Kolata
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2010003881A publication Critical patent/MX2010003881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee métodos para inhibir el crecimiento y proliferación de células de leucemia mieloide humana al administrar un agonista del receptor de trombopoyetina (TpoRA), un derivado o una variante del mismo a un individuo que padece MLA.
MX2010003881A 2007-10-09 2008-10-08 El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano. MX2010003881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99812607P 2007-10-09 2007-10-09
PCT/US2008/079205 WO2009048953A1 (en) 2007-10-09 2008-10-08 Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells

Publications (1)

Publication Number Publication Date
MX2010003881A true MX2010003881A (es) 2010-07-28

Family

ID=40549531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003881A MX2010003881A (es) 2007-10-09 2008-10-08 El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.

Country Status (12)

Country Link
US (1) US8530508B2 (es)
EP (1) EP2211855A4 (es)
JP (1) JP5393691B2 (es)
KR (1) KR101530402B1 (es)
CN (1) CN101888841B (es)
AU (1) AU2008310894B2 (es)
BR (1) BRPI0818346A2 (es)
CA (1) CA2709224C (es)
EA (1) EA022915B1 (es)
MX (1) MX2010003881A (es)
WO (1) WO2009048953A1 (es)
ZA (1) ZA201002499B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
WO2016205784A1 (en) * 2015-06-19 2016-12-22 The Scripps Research Institute Methods and compositions for producing activated natural killer cells and related uses
US20240010736A1 (en) * 2020-11-24 2024-01-11 Daegu Gyeongbuk Institute Of Science And Technology Novel anti-c-mpl antibody and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
AU9265698A (en) 1997-09-02 1999-03-22 Boehringer Mannheim Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia
JP2001521896A (ja) 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
US6630480B1 (en) * 1999-03-29 2003-10-07 Biochem Pharma Inc. Methods of treating leukemia
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) * 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
WO2001092306A2 (en) * 2000-05-31 2001-12-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
CA2435143A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Halogen compounds having thrombopoietin receptor agonism
WO2002062775A1 (fr) * 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
US20030171306A1 (en) * 2001-06-04 2003-09-11 Davis Stephen Thomas Cancer treatment method
EP2314586B1 (en) * 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4895807B2 (ja) * 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2007004765A (es) * 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
WO2007044982A2 (en) 2005-10-13 2007-04-19 Smithkline Beecham Corporation Methods for the preservation of platelet efficacy during storage
EP1951667A2 (en) 2005-11-23 2008-08-06 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US20100063301A1 (en) 2006-03-15 2010-03-11 Ligand Pharmaceuticals Inc Synthesis of thrombopoietin activity modulating compounds
WO2008073864A1 (en) 2006-12-12 2008-06-19 Smithkline Beecham Corporation Novel combinations
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
WO2009151862A1 (en) 2008-05-15 2009-12-17 Smithkline Beecham Corporation Method of treatment
EP2348858A4 (en) 2008-10-16 2013-06-12 Glaxosmithkline Llc PROCESS FOR THE TREATMENT OF THROMBOCYTOPENIA

Also Published As

Publication number Publication date
BRPI0818346A2 (pt) 2015-04-07
EA201070441A1 (ru) 2010-10-29
CN101888841B (zh) 2012-09-26
EP2211855A1 (en) 2010-08-04
CN101888841A (zh) 2010-11-17
JP2011500580A (ja) 2011-01-06
EP2211855A4 (en) 2011-12-07
CA2709224C (en) 2015-06-23
US8530508B2 (en) 2013-09-10
AU2008310894A1 (en) 2009-04-16
ZA201002499B (en) 2010-12-29
WO2009048953A1 (en) 2009-04-16
CA2709224A1 (en) 2009-04-16
US20100298398A1 (en) 2010-11-25
JP5393691B2 (ja) 2014-01-22
KR20100106952A (ko) 2010-10-04
AU2008310894B2 (en) 2012-07-26
KR101530402B1 (ko) 2015-06-19
EA022915B1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
MX2010002285A (es) Combinaciones de principios activos con propiedades insecticidas y acaricidas.
TW200700009A (en) Active compound combinations having insecticidal and acaricidal properties
WO2010056378A3 (en) Extracellular matrix compositions for the treatment of cancer
MY172151A (en) Certain chemical entities, compositions and methods
TN2011000222A1 (en) Melanocortin receptor agonists
NZ622566A (en) Chromobacterium bioactive compositions and metabolites
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2009010071A (es) Derivados de aril isoxazolina insecticidas.
MY153915A (en) Organic compounds
TN2010000020A1 (en) Polymer composite material with biocide functionality
MX2011013705A (es) Procedimiento para mejorar el crecimiento de las plantas y/o la emergencia precoz de los cultivos.
EA019744B9 (ru) Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
IN2013DN02552A (es)
IN2012DN02471A (es)
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
WO2009129208A8 (en) Compositions and methods of inducing endoplasmic reticulum stress reponse
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
MX2010003881A (es) El agonista del receptor de trombopoyetina (tpora) destruye las celulas de leucemia mieloide aguda de humano.
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
UA101158C2 (ru) ПЕПТИД RumC, КОТОРЫЙ ИМЕЕТ АНТИМИКРОБНУЮ АКТИВНОСТЬ

Legal Events

Date Code Title Description
FG Grant or registration